<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="768">
  <stage>Registered</stage>
  <submitdate>20/09/2005</submitdate>
  <approvaldate>28/09/2005</approvaldate>
  <actrnumber>ACTRN12605000538640</actrnumber>
  <trial_identification>
    <studytitle>Radiation sensitivity in prostate cancer patients</studytitle>
    <scientifictitle>Radiation sensitivity in prostate cancer patients</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Nil</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1.  To determine whether increased in vitro sensitivity to radiation-induced DNA damage in lymphocytes is a predictor of prostate cancer risk.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. To develop a set of biomarkers that predict the risk of abnormal tissue reaction to radiotherapy in prostate cancer patients.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. To identify dietary and genetic factors that have a strong modifying effect on the risk of abnormal tissue reaction to radiotherapy.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.  To determine whether increased in vitro sensitivity to radiation-induced DNA damage in lymphocytes is a predictor of prostate cancer risk.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. To develop a set of biomarkers that predict the risk of abnormal tissue reaction to radiotherapy in prostate cancer patients.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. To identify dietary and genetic factors that have a strong modifying effect on the risk of abnormal tissue reaction to radiotherapy.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>The first stage of the project is a case-control study involving 100 untreated Prostate cancer cases and 100 controls. Cases and controls will be matched for age, gender, familial history of cancer and smoking status.The second stage of the project is a prospective study aimed at determining whether the selected biomarkers predict abnormal tissue reaction in 100 localized Prostate cancer patients treated with RT who have ECOG 0-2 performance status and do not have a constant requirement for aperients or anti-diarrhoeal medication. Age, weight, tumour grade, family history of prostate cancer, use of anti-male hormone therapy and smoking status will be recorded.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>23/12/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>ROYAL ADELAIDE HOSPITAL</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>CSIRO</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ROYAL ADELAIDE HOSPITAL</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Julie Butters</name>
      <address>Radiation Oncology
Royal Adelaide Hospital (RAH) Cancer Centre
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 82224378</phone>
      <fax />
      <email>jbutters@mail.rah.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Eric Yeoh, MD FRCP (EDIN) FRCR</name>
      <address>Radiation Oncology
Royal Adelaide Hospital (RAH) Cancer Centre
Royal Adelaide Hospital
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 82224000</phone>
      <fax />
      <email>eyeoh@mail.rah.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>